Table 2 Demographic and clinical characteristics of subgroups analysed for the CGM and arginine tests
From: Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
All | Controls | Acute COVID-19 | Post COVID-19 | T2D | P | |
|---|---|---|---|---|---|---|
n | 35 | 15 | 10 | 10 | 10 | |
M/F, n | 21/14 | 10/5 | 4/6 | 7/3 | 6/4 | 0.24† |
0.9§ | ||||||
0.9# | ||||||
0.36* | ||||||
0.65ξ | ||||||
0.9ψ | ||||||
Age, years (mean ± s.e.m.) | 45.9 ± 2.1 | 47.2 ± 3.1 | 43.0 ± 4.7 | 46.9 ± 3.8 | 50.7 ± 3.9 | 0.84† |
0.99§ | ||||||
0.90# | ||||||
0.80* | ||||||
0.53ξ | ||||||
0.96ψ | ||||||
Smoking, n | 4 | 4 | 0 | 0 | 1 | 0.12† |
0.12§ | ||||||
0.61# | ||||||
0.9* | ||||||
0.9ξ | ||||||
0.9ψ | ||||||
Familiality T2D, n | 13 | 8 | 2 | 3 | 4 | 0.21† |
0.41§ | ||||||
0.68# | ||||||
0.9* | ||||||
0.62ξ | ||||||
0.9ψ | ||||||
BMI (mean ± s.e.m.) | 23.4 ± 0.6 | 23.3 ± 0.6 | 24.8 ± 2.1 | 22.4 ± 1.5 | 27.2 ± 0.3 | 0.72† |
0.94§ | ||||||
0.014# | ||||||
0.53* | ||||||
0.40ξ | ||||||
0.020ψ | ||||||
Hypertension (%) | 1 | 1 | 0 | 0 | 5 | 0.9† |
0.9§ | ||||||
0.022# | ||||||
0.9* | ||||||
0.032ξ | ||||||
0.032ψ | ||||||
Time after first symptom, d (mean ± s.e.m.) | 34.0 ± 5.7 | – | 22.9 ± 4.1 | 62.0 ± 3.2 | – | <0.001* |
Baseline clinical score (mean ± s.e.m.) | 3.1 ± 0.3 | – | 3.7 ± 0.3 | 2.0 ± 0.0 | – | <0.001* |
Therapies, n | ||||||
Hydroxychloroquine | 3 | 0 | 2 | 1 | 0 | 0.55* |
Antiviral | 3 | 0 | 3 | 0 | 0 | 0.06* |
Monoclonal antibody | 0 | 0 | 0 | 0 | 0 | 0.9* |
Steroids | 1 | 0 | 1 | 0 | 0 | 0.33* |
LMWH | 6 | 0 | 6 | 0 | 0 | 0.001* |
Antibiotics | 6 | 2 | 2 | 2 | 0 | 0.9* |
Diabetes-associated therapies, n | ||||||
Metformin | 0 | 0 | 0 | 0 | 6 | – |
Others | 0 | 0 | 0 | 0 | 0 | – |
No therapies | 0 | 0 | 0 | 0 | 4 | – |
